Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06056830 · ClinicalTrials.gov registry record · Phase 3
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
A Phase 3 study of Prostate Cancer and Prostatic Neoplasms, sponsored by Clarity Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 383
- Enrollment target
- 20
- Study locations
NCT06056830 is a Phase 3 study of Prostate Cancer and Prostatic Neoplasms that is actively recruiting participants, run by Clarity Pharmaceuticals. The registered enrollment target is 383 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06056830, a Phase 3 study of Prostate Cancer and Prostatic Neoplasms, is actively recruiting participants, sponsored by Clarity Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 383 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Conditions Studied
Interventions
- DRUG 64Cu-SAR-bisPSMA
Study Locations (20)
California
- Urology Group of Southern California - Los Angeles
- Greater Los Angeles VA Medical Center - Los Angeles
- Stanford University Medical Center - Stanford
Florida
- Mayo Clinic- Jacksonville - Jacksonville
- Biogenix Molecular, LLC - Miami
Michigan
- BAMF Health - Grand Rapids
- Corewell Health - Grand Rapids
Alabama
- University of Alabama Birmingham Hospital - Birmingham
Arizona
- Mayo Clinic- Phoenix - Phoenix
Illinois
- NorthShore University Health System - Glenview
Indiana
- Indiana University School of Medicine - Indianapolis
Minnesota
- Mayo Clinic- Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2023-12-21 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06056830
The ClinicalTrials.gov registry entry for NCT06056830 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (37% lower). The listed sponsor is Clarity Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which 64Cu-SAR-bisPSMA is the first listed.
NCT06056830 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT06056830 about?
NCT06056830 is a clinical study titled "Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy". The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
What is the current status of trial NCT06056830?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 383 participants. The study started on 2023-12-21. Estimated completion is 2026-09.
What conditions does trial NCT06056830 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostatic Neoplasms.
What interventions are being tested in trial NCT06056830?
The interventions under investigation include: 64Cu-SAR-bisPSMA (DRUG).
Who is sponsoring clinical trial NCT06056830?
This trial is sponsored by Clarity Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06056830 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.